| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 682.8 | 578.6 | 526.3 |
| Other income | 9.2 | 6.0 | 11.2 |
| Total income | 692.0 | 584.6 | 537.5 |
| Profit before exceptional items & tax | 51.0 | 59.2 | 75.1 |
| Exceptional items | -0.2 | -1.1 | -0.4 |
| Profit before tax | 50.8 | 58.1 | 74.7 |
| Net profit | 37.9 | 44.9 | 55.8 |
| Operating margin | 7.3% | 9.9% | 13.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -32.10% |
|---|---|
| Net profit, quarter on quarter | -15.60% |
| Revenue, year on year | +29.70% |
| Operating profit, year on year | -34.60% |
| Operating profit, quarter on quarter | -21.40% |
BSE results filing, NSE: ASTRAZEN. Figures extracted from the filing.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹5,848.50
- Market cap
- ₹14,621 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 86.2×Sector 47.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
- Value
- ₹0.02 Cr
AstraZeneca Pharma India Management Change
AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India reported receiving an ESG rating of 64 from Crisil ESG Ratings. The assessment was independently prepared using publicly available information.
AstraZeneca Pharma India Legal & Regulatory
The Delhi High Court has stayed the NPPA's demand notice regarding Betaloc-50 overcharging allegations until February 2027, subject to a 15% deposit of the total demand amount.
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India has been assigned an ESG rating of 57 by Crisil ESG Ratings based on publicly available information.